GOVX-B01 / GeoVax - LARVOL DELTA

GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire, GeoVax, Inc.) - "We are pleased with the progress of our three vaccine candidates for COVID-19. Safety, efficacy, and durability of protection (long-lasting) are the expected characteristics of our GV-MVA-VLP™ vaccine platform being used for constructing our vaccines....We will narrow to one vaccine candidate based on the safety, immunogenicity and protective efficacy....We plan to then proceed directly to manufacturing and initial human clinical testing for safety and immunogenicity....We expect BravoVax to provide testing and manufacturing support, as well as direct interactions with Chinese authorities, for a parallel regulatory pathway to what we will pursue in the United States. We have initiated discussions and submitted applications with U.S. funding agencies as well."

Clinical • Commercial • Licensing / partnership • Infectious Disease • Novel Coronavirus Disease